Incentives for smoking cessation
- Caitlin Notley(corresponding author),
- Sarah Gentry,
- Jonathan Livingstone-Banks,
- Linda Bauld,
- Rafael Perera,
- Jamie Hartmann-Boyce
- University of East Anglia,
- Oxford Cancer Intelligence Unit,
- University of Edinburgh
Research Output:
Contribution to journal
Review article
Research
Peer-reviewOpen access
Abstract
<p>Background Financial incentives, monetary or vouchers, are widely used in an attempt to precipitate, reinforce and sustain behaviour change, including smoking cessation. They have been used in workplaces, in clinics and hospitals, and within community programmes. Objectives To determine the long-term effect of incentives and contingency management programmes for smoking cessation. Search methods For this update, we searched the Cochrane Tobacco Addiction Group Specialised Register, clinicaltrials.gov, and the International Clinical Trials Registry Platform (ICTRP). The most recent searches were conducted in July 2018. Selection criteria We considered only randomised controlled trials, allocating individuals, workplaces, groups within workplaces, or communities to smoking cessation incentive schemes or control conditions. We included studies in a mixed-population setting (e.g. community, work-, clinic-or institution-based), and also studies in pregnant smokers. Data collection and analysis We used standard Cochrane methods. The primary outcome measure in the mixed-population studies was abstinence from smoking at longest follow-up (at least six months from the start of the intervention). In the trials of pregnant women we used abstinence measured at the longest follow-up, and at least to the end of the pregnancy. Where available, we pooled outcome data using a Mantel-Haenzel random-effects model, with results reported as risk ratios (RRs) and 95% confidence intervals (CIs), using adjusted estimates for cluster-randomised trials. We analysed studies carried out in mixed populations separately from those carried out in pregnant populations. Main results Thirty-three mixed-population studies met our inclusion criteria, covering more than 21,600 participants; 16 of these are new to this version of the review. Studies were set in varying locations, including community settings, clinics or health centres, workplaces, and outpatient drug clinics. We judged eight studies to be at low risk of bias, and 10 to be at high risk of bias, with the rest at unclear risk. Twenty-four of the trials were run in the USA, two in Thailand and one in the Phillipines. The rest were European. Incentives offered included cash payments or vouchers for goods and groceries, offered directly or collected and redeemable online. The pooled RR for quitting with incentives at longest follow-up (six months or more) compared with controls was 1.49 (95% CI 1.28 to 1.73; 31 RCTs, adjusted N = 20,097; I<sup>2</sup> = 33%). Results were not sensitive to the exclusion of six studies where an incentive for cessation was offered at long-term follow up (result excluding those studies: RR 1.40, 95% CI 1.16 to 1.69; 25 RCTs; adjusted N = 17,058; I<sup>2</sup> = 36%), suggesting the impact of incentives continues for at least some time after incentives cease. Although not always clearly reported, the total financial amount of incentives varied considerably between trials, from zero (self-deposits), to a range of between USD 45 and USD 1185. There was no clear direction of effect between trials offering low or high total value of incentives, nor those encouraging redeemable self-deposits. We included 10 studies of 2571 pregnant women. We judged two studies to be at low risk of bias, one at high risk of bias, and seven at unclear risk. When pooled, the nine trials with usable data (eight conducted in the USA and one in the UK), delivered an RR at longest follow-up (up to 24 weeks post-partum) of 2.38 (95% CI 1.54 to 3.69; N = 2273; I<sup>2</sup> = 41%), in favour of incentives. Authors’ conclusions Overall there is high-certainty evidence that incentives improve smoking cessation rates at long-term follow-up in mixed population studies. The effectiveness of incentives appears to be sustained even when the last follow-up occurs after the withdrawal of incentives. There is also moderate-certainty evidence, limited by some concerns about risks of bias, that incentive schemes conducted among pregnant smokers improve smoking cessation rates, both at the end of pregnancy and post-partum. Current and future research might explore more precisely differences between trials offering low or high cash incentives and self-incentives (deposits), within a variety of smoking populations.</p>
Research Output Information
Output type
Research Output:
Contribution to journal
Review article
Research
Peer-reviewOriginal language
EnglishArticle number
CD004307Journal (Volume, Issue Number)
The Cochrane database of systematic reviews (Volume 2019, Issue 7)Publication milestones
- Published - 17/07/2019
Publication status
Published - 17/07/2019
ISSN
1469-493XPublication IDs
- Scopus: 85069780469
- PubMed: 31313293
Funding Details
• JHB is funded by the National Institute of Health Research School for Primary Care Research (NIHR SPCR), UK.
Control Group: NV: vouchers not contingent on smoking status. (USD 8 per sample) , plus a USD 40 bonus for providing all 33 samples (total possible = USD 304). All received BA, a standard of care for smokers not seeking smoking treatment, then 7, 14, and 19 days later (subsequent sessions, 10 to 15 minutes). 4 sessions in total. and up to 8 weeks of NRT. To encourage participants to provide a breath CO sample regardless of whether they had been smoking, USD 1 was provided simply for providing the sample (non-contingent) regardless of results (total possible = USD 33) Experimental Group(s): CV: 14 days of vouchers for smoking abstinence (based on CO readings twice a day) after a 5-day smoking reduction period Reduction phase. USD 2 per test for a 25% reduction from baseline CO, USD 4 for 50% reduction, and USD 6 for a 75% or greater reduction Abstinence phase. Escalating schedule of payments provided increasing levels of payments in vouchers for each successive CO reading ≤ 6 ppm. USD 3 for the first sample, increasing by USD 0.50 for each consecutive negative test to USD 16.50 for the 28th consecutive abstinent breath sample, plus USD 10 bonuses provided every time 3 consecutive readings showed abstinence. Whenever a breath sample did not meet the criterion for abstinence, the participant earned no voucher and the payment schedule reverted to the initial USD 3 level, then after 3 consecutive abstinent samples the schedule returned to the payment level at which the reset occurred Total possible payment. Participants who completed all 19 days of samples and missed no more than 3 of the scheduled breath tests earned a USD 40 bonus voucher (total possible = USD 433 plus USD 33 for showing up = USD 466) Theoretical basis for intervention: not reported Duration of intervention: 19 days vouchers plus 8 weeks NRT Length of follow-up: 12 months PPA at 12 months, CO level ≤ 4 ppm and salivary cotinine ≤ 15 ng/ml At 1, 3, 6 months, the Timeline Followback interview for number of cigarettes each day, number of days of drug use, and number of heavy drinking days. At pretreatment and at 1 month, participants completed a Smoking Self-Efficacy Questionnaire New for 2019 update Funding: “Supported by 1 R01 DA023995 from the National Institute on Drug Abuse; a Senior Career Research Scientist Award from the Department of Veterans Affairs to the first author; and K05AA019681 from the National Institute on Alcohol Abuse and Alcoholism. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the official views of the National Institutes of Health.” Decarations of interest: not reported
New for 2015 update Funding was from Spanish Ministry of Science and Innovation grant PS12011-22804, and predoctoral grants BP12-037; FOundation for the Promotion of Applied Science Research and Technology in Asturias; and Spanish Ministry of Economy and Competitiveness (BES-2012-053988)
New for 2011 update. Additional information supplied by the authors Study funded by National Institute on Drug Abuse, and Dept of Veterans Affairs
Point prevalence abstinence at 6 months follow up, verified by exhaled CO ≤ 4 ppm and saliva cotinine level ≤ 10 ng/ml. Quit attempts (longest duration and number of quit attempts (no smoking for at least 24 hours)); cessation aids New for 2019 update ‘loose inclusion criteria for the study might have led to the inclusion of low-rate/nondaily/ light smokers who might simply stop smoking for a day in order to win. Such “cheating” was possible’ Funding: “This work was supported by the Hong Kong Council on Smoking and Health (COSH).” Decarations of interest: “Prof. Tai-hing Lam is the principal investigator of the FAMILY project, which was funded by the Hong Kong Jockey Club Charities Trust. All other authors do not have connection with the tobacco, alcohol, pharmaceutical or gaming industries, and nobody was substantially funded by these organizations.”
derwent intensive tobacco treatment specialist motivational interviewing, with brief follow-up motivational interviewing sessions at subsequent study visits, daily for the first week, then weekly for 8 weeks. Other additional interventions received included: enrolment in the National Cancer Institute’s free smokefreetxt text-messaging programme ( smokefree.gov); contingency management at each visit, by which participants received USD 5 gift cards for biochemically-confirmed smoking abstinence; and guided pharmacotherapy. Pharmacotherapeutic options offered were combination nicotine replacement therapy (patch/gum, patch/lozenge, or patch/nasal spray), bupropion, and varenicline. Participants were permitted to opt out of intervention components Theoretical basis for intervention: not reported Duration of intervention: 8 weeks Length of follow-up: 12 months PPA at 12 months, CO-verified, confirmed as exhaled CO 8 ppm. Smoking abstinence at 1, 2, 3, 4, 5, 6, 7 and 8 weeks, and at 3 and 6 months. Smoking intensity (total cigarettes per previous 7 days), reduction from baseline, and total cigarettes smoked New for 2019 update Funding: “This work was supported by the National Institute of Dental and Craniofacial Research and National Institutes of Health Research Training in Otolaryngology grant (grant number 2T32DC000027026) and the Maryland Department of Health and Mental Hygiene Cigarette Restitution Fund (grant number PHPA-G2034). The study sponsors had no role in study design or in the collection, analysis, or interpretation of data” Decarations of interest: not reported
PPA at 1 year, 2 years Validation: CO < 9 ppm and salivary cotinine This is the HIP study (Health Incentives Program). Great variability in outcome across sites (2-year follow-up cessation rates Int: 14 to 33%, Control: 9 to 27%), with 30% lost to follow-up at 2 years Study was funded by National Cancer Institute
New for 2019 update Trial encountered many problems and only 1 person was followed up at 6 months. Unpublished study, author provided outcome data by personal correspondence Funding: “This work was funded as part of TSA’s PhD studentship by the Medical Research Council and the Institute of Psychiatry, Psychology and Neuroscience (MRC/IoP Excellence Studentship). LSB is funded by a Cancer Research UK (CRUK)/BUPA Foundation Cancer Prevention Fellowship (C52999/ A19748). LSB and AM are members of the UK Centre for Tobacco and Alcohol Studies, a UK Clinical Research Collaboration Public Health Research: Centre of Excellence. Funding from the Medical Research Council, British Heart Foundation, Cancer Research UK, Economic and Social Research Council and the National Institute for Health Research under the auspices of the UK Clinical Research Collaboration is gratefully acknowledged 35 (MR/K/K023195/1) . Neither the funding bodies nor study sponsors had any role in study design; collection, management, analysis and interpretation of data; writing of the report and the decision to submit the report for publication.” Decarations of interest: “JS has contributed to UK guidelines which include consideration of the potential role of contingency management in the management of addiction problems (NICE, 2007; chaired by JS), and JS also chaired the broader scope pan-UK working group preparing the 2007 and 2017 editions of the ‘Orange Book’ (‘Guidelines on the Management of Drug Misuse & Dependence’) for the UK Departments of Health, providing guidance on management and treatment of drug dependence and misuse, which include guidance on possible inclusion of contingency management. JS’s institution has received support and funding from the Department of Health (England) and National Treatment Agency (England), and JS and JS’s institution have provided funded consultancy advice on possible novel addiction treatments, products and formulations to a range of pharmaceutical companies but these do not have any connection to the intervention being investigated in this paper. JS’s employer (King’s College London) has registered intellectual property on a novel buccal naloxone with which JS is involved, and JS has been named in a patent registration by a pharmaceutical company as inventor of a potential novel concentrated nasal spray, but these do not have any connection to the work being reported in this paper. A fuller account of JS’s interests is at http://www. kcl.ac.uk/ioppn/depts/addictions/people/hod.aspx. JS is supported by the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and King’s College London and is an NIHR Senior Investigator”
Study was funded by Centers for Disease Control and Prevention and by Pennsylvania Dept of Health
New for 2015 update Funding by NIH grant, and Helene Lycaki/Joe Young Sr funding through the State of Michigan
New for 2019 update In terms of misreport or no measurement 21 out of 41 self-reported at 12 months confirmed quit from Int group versus 4/19 control group Funding: “This study was supported by American Cancer Society (grant No. 125785-RSG-14-034-01CPPB). The funder/sponsor had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.” Decarations of interest: “Dr Quintiliani was a consultant on a research grant to Partners HealthCare Inc unrelated to the work presented in this article. No other conflicts are reported.”
New for 2019 update Funding: “Supported by a grant from the Vitality Institute to the University of Pennsylvania Center for Health Incentives and Behavioral Economics.” Decarations of interest: none reported by authors
New for 2015 update; Funded by grants from the US National Institute on Aging and the US National Institute for Child Health and Development Additional information supplied by the author
New for 2019 update Funding: “Supported by 1 RO1 DA13616 from the National Institute on Drug Abuse; two Senior Career Research Scientist Awards from the Department of Veterans Affairs (DJR and PMM); and K05AA019681 from the National Institute on Alcohol Abuse and Alcoholism. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs.” Decarations of interest: not reported
Study funded by National Institute on Drug Abuse
New for 2015 update Funding was from National Cancer Insitute grant R01 CA159932 (SDH) and National Institute of Aging grant RC2 AG036592 (DAA and KGV), and through in-kind support from the host company
Experimental Group(s): Participants could earn 4 vouchers with a total worth of EUR 350. The first EUR 50 voucher was received on the condition of biochemically validated smoking abstinence at the end of the smoking cessation training programme. The second and third EUR 50 vouchers could be earned when participants were abstinent 3 and 6 months after finishing the cessation programme. At the end of the study (12 months after completion of the cessation programme), participants could earn an additional EUR 200 voucher The vouchers were sent by email in the form of a digital code that could be exchanged in a web shop for a large range of products or activities Control Group: A smoking cessation group training programme consisting of a 90-minute session each week for 7 weeks. The pre-existing training programme was designed to help participants to initiate a quit attempt and guide them through the first few difficult weeks of quitting smoking, with an important role for group dynamics and peer support. Participants quit together at the start of the third session, and had quit smoking for about 1 month at the last session Primary: continuous abstinence at 12 months. Cut-off point 9 ppm Secondary outcomes: 3 and 6 months biochemically validated abstinence, and self-reported abstinence New for 2019 update Funding: “This study is funded by the Dutch Cancer Society (grant number: UM 2015-7943)” Decarations of interest: “DK received an unrestricted grant from Pfizer for an investigator-initiated trial on the effectiveness of practice nurse counseling and varenicline for smoking cessation in primary care (Dutch Trial Register NTR3067). OS received institutional research grants from Pfizer for investigator-initiated trials.”
Continuous abstinence between 6 and 18 months, CO-verified (0 to 3 ppm) and cotinine,10 ng/ml Quit attempts during the intervention phase (number, duration and dates), cigarette consumption, motivation to quit, confidence in ability to quit, Use of the online smoking cessation programme New for 2019 update Previously listed as ongoing. Relatively affluent population compared to other countries Funding: “From the Institute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland. The study was funded by the Swiss Tobacco Prevention Fund (Swiss Federal Office of Public Health), grant 11.001733. Dr. Etter’s salary was paid by the University of Geneva. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.” Decarations of interest: “The Swiss Tobacco Prevention Fund, which funded the study, suggested that the follow-up should be extended to 12 instead of 6 months after the final incentives were received, but had no other role in the conduct of the study.”
Additional information supplied by the author Funding: ”This study and the preparation of this report were funded by National Institutes of Health grants R21-DA021836; R21-DA029215; R01-DA013444; R01-DA027615; R01-DA024667; P30-DA023918 and P50-DA092410
New for 2015 update Funding: grant from Robert Wood Johnson Foundation Smoke-Free Families Program, + support from local businesses and healthcare facilities
12-month PPA confirmed by CO breath test and urinary cotinine. Expired breath CO ≤ 4 ppm and urine cotinine < 100 ng/mL (or solely breath CO if participant was using NRT). Treatment programme participation, medications New for 2019 update Half of participants in each intervention group randomised to receive incentives. N randomised to incentives not reported. 25 participants (4%) experienced a serious adverse event: 16 were hospitalised for psychiatric exacerbations, 7 were hospitalised for medical reasons (pneumonia, lung cancer, and heart attack), and 5 study participants died Funding: “This research received financial support from the Centers for Medicare and Medicaid Services (Medicaid Incentives for the Prevention of Chronic Diseases grant 1B1CMS330880) and from the New Hampshire Department of Health and Human Services (NHDHHS).” Decarations of interest: “Dr. Brunette reports receipt of research funding from Alkermes. The other authors report no financial relationships with commercial interests.”
Additional information supplied by the author New for 2008 update Study funded by Arizona Biomedical Research Commission
This project was supported by the National Institute for Health Research (NIHR), via Cochrane Infrastructure and Cochrane Programme Grant funding to the Cochrane Tobacco Addiction Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health and Social Care. JHB is also part-funded by the NIHR Oxford Biomedical Research Centre (BRC).
FundersFunding numbers
Biomedical Research Centre for Mental Health
-Dept of Veterans Affairs
-Dutch Cancer Society
UM 2015-7943
Dutch Trial Register
NTR3067
FOundation for the Promotion of Applied Science Research and Technology in Asturias
-Hong Kong Council on Smoking and Health
-Hong Kong Jockey Club Charities Trust
-NHDHHS
-National Cancer Insitute
R01 CA159932
National Institute of Health Research School for Primary Care Research
-National Institutes of Health Research Training in Otolaryngology
2T32DC000027026
New Hampshire Department of Health and Human Services
-Pennsylvania Dept of Health
-Spanish Ministry of Economy and Competitiveness
BES-2012-053988
State of Michigan
-Swiss Federal Office of Public Health
11.001733
Swiss Tobacco Prevention Fund
-US National Institute on Aging
-University of Pennsylvania Center for Health Incentives
-Vitality Institute
-NIH
P50-DA092410, R21-DA021836, R21-DA029215, R01-DA024667, P30-DA023918, R01-DA027615, R01-DA013444
NIDA
-NIAAA
-ACS
125785-RSG-14-034-01CPPB
NIA
RC2 AG036592
NCI
-NIDCR
-VA
K05AA019681
RWJF
-CMS
1B1CMS330880
DHMH
PHPA-G2034
ABRC
-Pfizer UK
-King's College London
-South London and Maudsley NHS Foundation Trust
-MRC
-ESRC
-NIHR
MR/K/K023195/1
BHF
-CRUK
-Bupa Foundation
C52999/ A19748
MICINN
PS12011-22804, BP12-037
Pat Cosh Trust Fund
-Sustainable Development Goals
- SDG 3 Good Health and Well
